Rohan Shotton, Rachel Broadbent, Alia Alchawaf, Mohamed Bakri Mohamed, Adam Gibb, Nicolás Martinez-Calle, Christopher P Fox, Mark Bishton, Alexandra Pender, Mary Gleeson, David Cunningham, Andrew John Davies, Sina Yadollahi, Toby A Eyre, Graham P Collins, Faouzi Djebbari, Shireen Kassam, Paula Garland, Emily Watts, Wendy Osborne, Wiliam M Townsend, Rachael Pocock, Matthew J Ahearne, Fiona Miall, Xin Wang, Kim Linton
INTRODUCTION: Bendamustine is among the most effective chemotherapeutics for indolent B-cell non-Hodgkin lymphomas (iNHL), but trial reports of significant toxicity, including opportunistic infections and excess deaths, led to prescriber warnings. We conducted a multicentre observational study evaluating bendamustine toxicity in real-world practice. METHODS: Patients receiving at least one dose of bendamustine (B) +/- rituximab (R) for iNHL were included. Demographics, lymphoma and treatment details and grade 3-5 adverse events (AEs) were analysed...
November 15, 2023: Blood Advances